Antiprotease in preventing the invasive potential of pancreatic cancer cells

Journal of the Pancreas

Volumn 8, Issue 4, 2007, Pages 501-508

  Takahashi, Hiroki ^a   Sawai, Hirozumi ^a   Funahashi, Hitoshi ^a   Matsuo, Yoichi ^a   Yasuda, Akira ^a   Ochi, Nobuo ^a   Sato, Mikinori ^a   Okada, Yuji ^a   Takeyama, Hiromitsu ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Gabexate; Neoplasm invasiveness; NF kappa B; Pancreatic neoplasms; Protease inhibitors

Indexed keywords

BATIMASTAT; CYSTEINE PROTEINASE; GABEXATE MESILATE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; NEUROTROPHIC FACTOR; PROTEASOME INHIBITOR; PROTEINASE INHIBITOR; RO 28 2653; SALAZOSULFAPYRIDINE; SALICYLIC ACID; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; TANOMASTAT; UNCLASSIFIED DRUG; CYSTEINE PROTEINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER INVASION; CLINICAL TRIAL; CONFERENCE PAPER; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; LIVER METASTASIS; LOW DRUG DOSE; METASTASIS POTENTIAL; NONHUMAN; PANCREAS CANCER; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PANCREAS TUMOR; PATHOLOGY; REVIEW; TUMOR CELL LINE;

CELL LINE, TUMOR; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; NF-KAPPA B; PANCREATIC NEOPLASMS; SERINE PROTEINASE INHIBITORS;

EID: 34547929471     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (59)

1. Takahashi T, Ishikura H, Motohara T, Okushiba S, Dohke M, Katoh H. Perineural invasion by ductal adenocarcinoma of the pancreas. J Surg Oncol 1997; 65:164-70.
2. Hirai I, Kimura W, Ozawa K, Kudo S, Suto K, Kuzu H, Fuse A. Perineural invasion in pancreatic cancer. Pancreas 2002; 24:15-25.
3. Ozaki H, Hiraoka T, Mizumoto R, Matsuno S, Matsumoto Y, Nakayama T, et al. The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection. Surg Today 1999; 29:16-22.
4. Friess H, Yamanaka Y, Büchler M, Ebert M, Beger HG, Gold LI, Korc M. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993; 105:1846-56.
5. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial-cell-line derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993; 260:1130-2.
6. Henderson CE, Phillips HS, Pollock RA, Davies AM, Lemeulle C, Armanini M, et al. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science 1994; 266:1062-4.
7. Okada Y, Takeyama H, Sato M, Morikawa M, Sobue K, Asai K, et al. Experimental implication of celiac ganglionotropic invasion of pancreatic-cancer cells bearing c-ret proto-oncogene with reference to glial-cell-line-derived neurotrophic factor (GDNF). Int J Cancer 1999; 81:67-73.
8. Funahashi H, Takeyama H, Sawai H, Furuta A, Sato M, Okada Y, et al. Alteration of Expression by Glial Cell Line-Derived Neurotrophic Factor (GDNF) in Human Pancreatic Cancer Cells. Pancreas 2003; 27:190-6.
9. Takahashi H, Funahashi H, Sawai H, Sakamoto M, Matsuo Y, Yamamoto M, et al. Glial cell line-derived neurotrophic factor enhances nuclear factor-kappaB activity and invasive potential in human pancreatic cancer cells. Pancreas 2004; 29:22-7.
10. Chen HM, Chen JC, Hwang TL, Jan YY, Chen MF. Prospective and randomized study of gabexate mesilate for the treatment of severe acute pancreatitis with organ dysfunction. Hepatogastroenterology 2000; 47:1147-50.
11. Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatograpby. Gabexate in digestive endoscopy. Italian Group. N Engl J Med 1996; 335:919-23.
12. Aosasa S, Ono S, Mochizuki H, Tsujimoto H, Ueno C, Matsumoto A. Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor alpha production of monocytes. Shock 2001; 15:101-5.
13. Uchiba M, Okajima K, Kaun C, Binder BF, Wojta J. Gabexate mesilate, a synthetic anticoagulant, inhibits the expression of endothelial leukocyte adhesion molecules in vitro. Crit Care Med 2003; 31:1147-53.
14. Wang CY, Mayo MW, Baldwin AS. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996; 274:784-7.
15. Arlt A, Vorndamm J, Breitenbroich M, Fölsch UR, Kalthoff H, Schmidt WE, Schäfer H. Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 2001; 20:859-68.
16. Arlt A, Vorndamm J, Müerköster S, Yu H, Schmidt WE, Fölsch UR, Schäfer H. Autocrine production of interleukin 1beta confers constitutive nuclear factor kappaB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res 2002; 62:910-6.
17. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001; 20:4188-97.
18. Huang S, DeGuzman A, Bucana CD, Fidler IJ. Nuclear factor-kappaB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin Cancer Res 2000; 6:2573-81.
19. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ, Sledge GW. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997; 17:3629-39.
20. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999; 5:119-27.
21. Scaife CL, Kuang J, Wills JC, Trowbridge DB, Gray P, Manning BM, et al. Nuclear factor kappaB inhibitors induce adhesion-dependent colon cancer apoptosis: implications for metastasis. Cancer Res 2002; 62:6870-8.
22. Shah SA, Potter MW, McDade TP, Ricciardi R, Peragini RA, Elliott PJ, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001; 82:110-22.
23. Müerköster S, Arlt A, Witt M, Gehrz A, Haye S, March C, et al. Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer 2003; 104:469-76.
24. McDade TP, Perugini RA, Vittimberga FJ, Carrigan RC, Callery MP. Salicylates inhibit NF-kappaB activation and enhance TNF-alpha-induced apoptosis in human pancreatic cancer cells. J Surg Res 1999; 83:56-61.
25. DeClerck YA, Imren S. Protease inhibitors: role and potential therapeutic use in human cancer. Eur J Cancer 1994; 30A:2170-80.
26. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993; 9:541-73.
27. Wang W, Abbruzzese JL, Evans DB, Chiao PJ. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene 1999; 18:4554-63.
28. Cantero D, Friess H, Deflorin J, Zimmermann A, Brundler MA, Riesle E, et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 1997; 75:388-95.
29. Sawai H, Okada Y, Funahashi H, Matsuo Y, Takahashi H, Takeyama H, Manabe T. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression. BMC Cell Biol 2006; 7:8.
30. Sawai H, Liu J, Reber HA, Hines OJ, Eibl G. Activation of peroxisome proliferator-activated receptor-gamma decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system. Mol Cancer Res 2006; 4:159-67.
31. Zhang H, Ma G, Dong M, Zhao M, Shen X, Ma Z, Guo K. Epidermal growth factor promotes invasiveness of pancreatic cancer cells through NF-kappaB-mediated proteinase productions. Pancreas 2006; 32:101-19.
32. Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, Abbruzzese JL, et al. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2002; 1:1243-53.
33. Uchima Y, Sawada T, Nishihara T, Maeda K, Ohira M, Hirakawa K. Inhibition and mechanism of action of a protease inhibitor in human pancreatic cancer cells. Pancreas 2004; 29:123-31.
34. Takahashi H, Funahashi H, Sawai H, Matsuo Y, Yamamoto M, Okada Y, et al. Synthetic Serine Protease Inhibitor, Gabexate Mesilate, Prevents Nuclear Factor-kappaB Activation and Increases TNF-alpha-Mediated Apoptosis in Human Pancreatic Cancer Cells. Dig Dis Sci 2007; Mar 15.
35. Johansson N, Ahonen M, Kähäri VM. Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci 2000; 57:5-15.
36. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17:463-16.
37. Cox G, O'Byrne KJ. Matrix metalloproteinases and cancer. Anticancer Res 2001; 21:4207-19.
38. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999; 274:21491-4.
39. Gress TM, Müller-Pillasch F, Lerch MM, Friess H, Büchler M, Adler G. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995; 62:407-13.
40. Gong YL, Xu GM, Huang WD, Chen LB. Expression of matrix metalloproteinases and the tissue inhibitors of metalloproteinases and their local invasiveness and metastasis in Chinese human pancreatic cancer. J Surg Oncol 2000; 73:95-9.
41. Tan X, Egami H, Abe M, Nozawa F, Hirota M, Ogawa M. Involvement of MMP-7 in invasion of pancreatic cancer cells through activation of the EGFR mediated MEK-ERK signal transduction pathway. J Clin Pathol 2005; 58:1242-8.
42. Okada Y, Eibl G, Duffy JP, Reber HA, Hines OJ. Glial cell-derived neurotrophic factor upregulates the expression and activation of matrix metalloproteinase-9 in human pancreatic cancer. Surgery 2003; 134:293-9.
43. Kilian M, Gregor JI, Heukamp I, Hanel M, Ahlgrimm M, Schimke I, et al. Matrix metalloproteinase inhibitor RO 28-2653 decreases liver metastasis by reduction of MMP-2 and MMP-9 concentration in BOP-induced ductal pancreatic cancer in Syrian Hamsters: inhibition of matrix metalloproteinases in pancreatic cancer. Prostaglandins Leukot Essent Fatty Acids 2006; 75:429-34.
44. Zervos EE, Shafii AE, Haq M, Rosemurgy AS. Matrix metalloproteinase inhibition suppresses MMP-2 activity and activation of PANC-1 cells in vitro. J Surg Res 1999; 84:162-7.
45. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA; Marimastat Pancreatic Cancer Study Group. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001; 19:3447-55.
46. Moore MJ, Hamm J, Dancey J, Eisenberg PD, Dagenais M, Fields A, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21:3296-302.
47. Baker AH, Ahonen M, Kähäri VM. Potential applications of tissue inhibitor of metalloproteinase (TIMP) overexpression for cancer gene therapy. Adv Exp Med Biol 2000; 465:469-83.
48. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA. Matrix metalloproteinease: a review. Crit Rev Oral Biol Med 1993; 4:197-250.
49. Bloomston M, Shafii A, Zervos EE, Rosemurgy AS. TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis. J Surg Res 2002; 102:39-44.
50. Bloomston M, Shafii A, Zervos E, Rosemurgy AS. TIMP-1 antisense gene transfection attenuates the invasive potential of pancreatic cancer cells in vitro and inhibits tumor growth in vivo. Am J Surg 2005; 189:675-9.
51. Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, Hanahan D, Joyce JA. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 2006; 20:543-56.
52. Turk V, Kos J, Turk B. Cysteine cathepsins (proteases). On the main stage of cancer? Cancer Cell 2004; 5:409-10.
53. Frosch BA, Berquin I, Emmert-Buck MR, Moin K, Sloane BF. Molecular regulation, membrane association and secretion of tumor cathepsin B. APMIS 1999; 107:28-37.
54. Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, Kramer M, et al. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J Biol Chem 1991; 266:5147-52.
55. Niedergethmann M, Wostbrock B, Sturm JW, Willeke F, Post S, Hildenbrand R. Prognostic impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma. Pancreas 2004; 29:204-11.
56. Yanamandra N, Gumidyala KV, Waldron KG, Gujrati M, Olivero WC, Dinh DH, et al. Blockade of cathepsin B expression in human glioblastoma cells is associated with suppression of angiogenesis. Oncogene 2004; 23:2224-30.
57. Lakka SS, Gondi CS, Yanamandra N, Olivero WC, Dinh DH, Gujrati M, Rao JS. Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 2004; 23:4681-9.
58. Li W, Ding F, Zhang L, Liu Z, Wu Y, Luo A, et al. Overexpression of stefin A in human esophageal squamous cell carcinoma cells inhibits tumor cell growth, angiogenesis, invasion, and metastasis. Clin Cancer Res 2005; 15:8753-62.
59. Greenspan PD, Clark KL, Tommasi RA, Cowen SD, McQuire LW, Farley DL, et al. Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug design. J Med Chem 2001; 20:4524-34.